Table 3. A Comparison of the Use of PRETEXT in Risk Stratification Schemes for Hepatoblastomaa,b

COG (AHEP-0731) SIOPEL (SIOPEL-3, -3HR, -4, -6) GPOHJPLT (JPLT-2 and -3)
Very low risk PRETEXT I or II; pure fetal histology; primary resection at diagnosis
Low risk/standard riskPRETEXT I or II of any histology with primary resection at diagnosis PRETEXT I, II, or IIIPRETEXT I, II, or IIIPRETEXT I, II, or III
Intermediate riskbPRETEXT II, III, or IV unresectable at diagnosis; or V+c, P+, E+; SCU histology PRETEXT IV or any PRETEXT with rupture; or N1, P2, P2a, V3, V3a; or multifocal
High riskbAny PRETEXT with M+; AFP level <100 ng/mL Any PRETEXT; V+, P+, E+, M+; SCU histology; AFP level <100 ng/mL; tumor ruptureAny PRETEXT with V+, E+, P+, M+ or multifocalAny PRETEXT with M1 or N2; or AFP level <100 ng/mL

AFP = alpha-fetoprotein; COG = Children's Oncology Group; GPOH = Gesellschaft für Pädiatrische Onkologie und Hämatologie (Society for Paediatric Oncology and Haematology); JPLT = Japanese Study Group for Pediatric Liver Tumor; PRETEXT = PRE-Treatment EXTent of disease; SCU = small cell undifferentiated; SIOPEL = International Childhood Liver Tumors Strategy Group.

aAdapted from Czauderna et al.[58]

bRefer to Table 1 for more information about the annotations used in PRETEXT.

cThe COG and PRETEXT definitions of vascular involvement differ.

From: Childhood Liver Cancer Treatment (PDQ®)

Cover of PDQ Cancer Information Summaries
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.